Phathom Pharmaceuticals Inc
$ 13.47
2.12%
20 Apr - close price
- Market Cap 1,047,683,000 USD
- Current Price $ 13.47
- High / Low $ 13.66 / 13.00
- Stock P/E N/A
- Book Value -6.13
- EPS -3.03
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -34.89 %
- 52 Week High 18.31
- 52 Week Low 2.21
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Analyst Target Price
$23.70
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-10-30 | 2025-08-07 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-10 |
| Reported EPS | -0.08 | -0.15 | -0.79 | -1.07 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 | -0.84 | -0.89 |
| Estimated EPS | -0.42 | -0.47 | -0.91 | -1.066 | -1.08 | -1.49 | -1.38 | -1.31 | -1.08 | -0.89 | -0.98 | -1.26 |
| Surprise | 0.34 | 0.32 | 0.12 | -0.004 | 0.03 | 0.17 | -0.18 | -0.11 | -0.31 | 0.13 | 0.14 | 0.37 |
| Surprise Percentage | 80.9524% | 68.0851% | 13.1868% | -0.3752% | 2.7778% | 11.4094% | -13.0435% | -8.3969% | -28.7037% | 14.6067% | 14.2857% | 29.3651% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAT
2026-04-20 12:09:31
Phathom Pharmaceuticals (Nasdaq: PHAT) announced it will report its first quarter 2026 financial results and provide a business update via a live webcast on Thursday, April 30, 2026, at 8:00 am EDT. The company, which commercializes vonoprazan as VOQUEZNA products for GERD and H. pylori, will make a recording of the webcast available for 90 days. This follows a consistent pattern of pre-announcing earnings dates, which has previously correlated with positive stock price movements.
2026-04-20 12:09:31
Phathom Pharmaceuticals (Nasdaq: PHAT) is scheduled to report its first-quarter 2026 financial results and provide a business update via a live webcast on Thursday, April 30, 2026, at 8:00 am EDT. The company specializes in developing and commercializing treatments for gastrointestinal diseases, including vonoprazan, marketed as VOQUEZNA for GERD and H. pylori infection. A recording of the webcast will be available for 90 days on their investor relations website.
2026-04-14 21:40:06
Phathom Pharmaceuticals saw its stock surge by 125% after the FDA granted its Citizen Petition, affirming Voquezna's new chemical entity (NCE) exclusivity. This ruling prevents generic versions from entering the market until at least 2029, a significant win following initial concerns about Voquezna's exclusivity length for both erosive and non-erosive gastroesophageal reflux disease indications. The decision also invalidated a paragraph IV certification for a generic version, strengthening Phathom's market position.
2026-04-11 23:39:00
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), indicating strong sentiment across all horizons and an exceptional 114.3:1 risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, supported by multi-timeframe signal analysis. The analysis suggests an overweight bias for PHAT, targeting a 28.6% gain with minimal risk.
2026-04-08 06:39:00
This article announces an ARS SEC filing by Phathom Pharmaceuticals, Inc. (PHAT) on April 7, 2026, which is available as a PDF document. It also provides an overview of the company's stock performance rankings, latest news, and other recent SEC filings, including a DEF 14A and Form 4 insider trading activity. Key financial data like market cap, float, industry, and sector are also listed.
2026-04-07 05:39:23
Phathom Pharmaceuticals announced its participation in upcoming investor conferences in April, including the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference. Management plans to engage in one-on-one meetings at both events and present a fireside chat at the Needham Conference. The company, focused on GI diseases, will discuss its commercialization of vonoprazan (VOQUEZNA®) for various conditions.
